Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1999 Sep 28;96(20):10958-61.
doi: 10.1073/pnas.96.20.10958.

Latent reservoirs of HIV: obstacles to the eradication of virus

T W Chun  1 , A S Fauci
Affiliations

Latent reservoirs of HIV: obstacles to the eradication of virus

T W Chun et al. Proc Natl Acad Sci U S A. .

Abstract

The use of highly active antiretroviral therapy (HAART) in the treatment of HIV-1-infected individuals has provided a considerable amount of information regarding the dynamics of viral replication and has resulted in enormous advances in HIV therapeutics. The profound suppression of plasma viremia in HIV-infected individuals receiving HAART has resulted in a highly beneficial clinical effect and a dramatic decrease in the death rate attributable to AIDS. Nonetheless, the persistance of reservoirs of HIV, including latently infected, resting CD4+ T cells that can give rise to infectious HIV upon stimulation in vitro, has posed a sobering challenge to the long-term control or eradication of HIV in infected individuals receiving HAART. Although a recent study has demonstrated th at the size of the pool of latently infected, resting CD4+ T cells can be markedly diminished with intermittent interleukin (IL-2) and continuous HAART, complete eradication of HiV in infected individuals remains extremely problematic. Here we discuss recent developments in studies of the latent reservoir of HIV in patients receiving HAART and implications for the long-term treatment of infected individuals and eradication of the infection.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gulick R M, Mellors J W, Havlir D, Eron J J, Gonzalez C, McMahon D, Richman D D, Valentine F T, Jonas L, Meibohm A, et al. N Engl J Med. 1997;337:734–739. - PubMed
    1. Hammer S M, Squires K E, Hughes M D, Grimes J M, Demeter L M, Currier J S, Eron J J, Jr, Feinberg J E, Balfour H H, Jr, Deyton L R, et al. N Engl J Med. 1997;337:725–733. - PubMed
    1. Palella F J, Jr, Delaney K M, Moorman A C, Loveless M O, Fuhrer J, Satten G A, Aschman D J, Holmberg S D. N Engl J Med. 1998;338:853–860. - PubMed
    1. Detels R, Munoz A, McFarlane G, Kingsley L A, Margolick J B, Giorgi J, Schrager L K, Phair J P. J Am Med Assoc. 1998;280:1497–1503. - PubMed
    1. Vittinghoff E, Scheer S, O’Malley P, Colfax G, Holmberg S D, Buchbinder S P. J Infect Dis. 1999;179:717–720. - PubMed

Substances